Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

570.60INR
24 May 2019
Change (% chg)

Rs5.85 (+1.04%)
Prev Close
Rs564.75
Open
Rs569.20
Day's High
Rs572.50
Day's Low
Rs559.45
Volume
1,796,355
Avg. Vol
2,433,946
52-wk High
Rs678.45
52-wk Low
Rs483.75

Latest Key Developments (Source: Significant Developments)

Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC
Monday, 1 Apr 2019 

April 1 (Reuters) - Cipla Ltd ::PULMATRIX ENTERS INTO BINDING TERM SHEET WITH CIPLA TECHNOLOGIES LLC FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PULMAZOLE.PULMATRIX - BINDING TERM SHEET EXECUTED ON APRIL 1, 2019 LAYS GROUNDWORK FOR ENTRY INTO A DEFINITIVE AGREEMENT DURING 2ND QUARTER OF 2019.PULMATRIX - CIP TEC TO MAKE AN UPFRONT PAYMENT OF $22 MILLION TO CO IN EXCHANGE FOR ASSIGNMENT OF ALL RIGHTS TO PULMAZOLE TO CIP TEC.PULMATRIX - ENTRY INTO DEFINITIVE AGREEMENT IS CONTINGENT UPON, CO HAVING AT LEAST $15 MILLION IN UNENCUMBERED FUNDS.PULMATRIX INC - PULMATRIX TO RETAIN RIGHT TO RECEIVE 50% OF FREE CASH FLOW FROM FUTURE SALES OF PULMAZOLE.PULMATRIX INC - CO TO REMAIN PRIMARILY RESPONSIBLE FOR IMPLEMENTATION OF CLINICAL DEVELOPMENT OF PULMAZOLE.PULMATRIX INC - CIP TEC WILL BE RESPONSIBLE FOR IMPLEMENTATION OF COMMERCIALIZATION OF PULMAZOLE.  Full Article

Cipla, Unit Cipla USA Announce Phased Launch Of Generic Cinacalcet Hydrochloride Tablets In USA
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Cipla Ltd ::CO, UNIT CIPLA USA ANNOUNCED A PHASED LAUNCH OF GENERIC CINACALCET HYDROCHLORIDE TABLETS IN USA.SAYS "LAUNCH IS A SUBJECT OF ONGOING LITIGATION".  Full Article

Cipla Says Co, Wellthy Therapeutics Enter Partnership
Monday, 18 Feb 2019 

Feb 18 (Reuters) - Cipla Ltd ::CO & WELLTHY THERAPEUTICS ENTER PARTNERSHIP TO OFFER COMBINATION OF PHARMACOTHERAPY & DIGITAL THERAPEUTICS OF DIABETOLOGY & CARDIOLOGY.DEAL WORTH CASH CONSIDERATION OF 105 MILLION RUPEES.  Full Article

Cipla Gets Final Nod For Generic Version Of Eli Lilly & Co.'s Adcirca
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Cipla Ltd ::SAYS RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ELI LILLY & CO.'S ADCIRCA.SAYS PRODUCT IS AVAILABLE FOR SHIPPING IMMEDIATELY.  Full Article

India's Cipla Dec-Qtr Consol Profit Falls Over 17 Pct
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Cipla Ltd ::DEC QUARTER CONSOL NET PROFIT 3.32 BILLION RUPEES VERSUS 4.01 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL NET PROFIT WAS 3.72 BILLION RUPEES.DEC QUARTER CONSOL NET SALES 39.06 BILLION RUPEES VERSUS 38.34 BILLION RUPEES LAST YEAR.SAYS DEC-QUARTER TOTAL TAX EXPENSE 1.26 BILLION RUPEES.  Full Article

Cipla Gets USFDA Final Approval For Generic Version Of Depo-Provera
Monday, 28 Jan 2019 

Jan 28 (Reuters) - Cipla Ltd ::GETS FINAL APPROVAL FOR GENERIC VERSION OF PFIZER’S DEPO-PROVERA® (MEDROXYPROGESTERONE INJECTABLE, 150MG/ML ).  Full Article

Cipla Gets Final Approval For Generic Version Of Roche's Valcyte
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ROCHE'S VALCYTE (VALGANCICLOVIR TABLETS 450MG).  Full Article

Cipla Sees Multiple Headwinds Impact Reported Performance In H2
Monday, 5 Nov 2018 

Nov 5 (Reuters) - Cipla Ltd ::"AS WE ENTER THE SECOND HALF OF THIS FISCAL, MULTIPLE HEADWINDS ARE LIKELY TO IMPACT OUR REPORTED PERFORMANCE".  Full Article

Cipla Gets Final Nod For Generic Version Of Aralez Pharmaceuticals' Toprol Xl ER Tablets
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Cipla Ltd ::RECEIVES FINAL APPROVAL FOR GENERIC VERSION OF ARALEZ PHARMACEUTICALS, INC.'S TOPROL XL ER TABLETS 50MG, 100MG, 200MG..  Full Article

Cipla Gets Final Approval For Generic Reyataz
Friday, 10 Aug 2018 

Aug 10 (Reuters) - Cipla Ltd ::CIPLA RECEIVES FINAL APPROVAL FOR GENERIC REYATAZ.DRUG INDICATED FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR TREATMENT OF HIV-1 INFECTION.  Full Article

UPDATE 1-India's Sun Pharma Q3 profit jumps four-fold on strong U.S. show

Feb 12 India's largest drugmaker by market value Sun Pharmaceutical Industries Ltd posted a nearly four-fold jump in quarterly profit on Tuesday, breezing past estimates on strong sales in the U.S. market.